MaaT Pharma's Stock Rebounds Nearly 7% After Yesterday's Collapse, Ahead of CHMP Vote
However, the stock remains significantly distant from its pre-CHMP adverse signal levels, and the formal vote of the European committee remains the central issue in the coming weeks.
A Technical Rebound of 6.88% Only Partially Corrects Yesterday's Crash
MaaT Pharma's stock has recovered 6.88% to €3.1850 at mid-session, after losing 56% the previous day. This surge places the stock among the highest gains in the CAC All Shares, while the CAC 40 is up 0.48% and the SBF 120 has advanced 0.52%. However, the movement is still marginal compared to the recent drop: the weekly loss still reaches 56.01%, and the decline over three months is almost identical at 56.84%. The price is now very far from its moving averages, at nearly 49% below the MM20 (€6.26) and 40% below the MM200 (€5.34). The 20 RSI reflects the selling exhaustion following Thursday's shock, which partly explains the technical rebound observed during the session but is not enough to reverse the underlying trend. The support at €2.98, touched the previous day, acts as an immediate floor.
The Formal CHMP Vote in June Remains a Central Milestone for the Lyon-based Biotech
Thursday's plunge follows information conveyed by the Committee for Medicinal Products for Human Use of the European Medicines Agency, which would lean towards a negative opinion on Xervyteg (MaaT013), a treatment for acute graft-versus-host disease. The company is seeking conditional marketing authorization, and the committee's formal vote is expected in June. This regulatory horizon continues to shape the profile of the case, with the course now more than 36% below its level a year ago. On the agenda, MaaT Pharma will publish its first quarter 2026 revenue on May 26. This appointment will occur before the European decision and will provide an initial financial reading to a market now awaiting the outcome of the CHMP process.
